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Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain cancer, with a median survival of less
than 2 years after diagnosis with current available therapies. The tumor microenvironment serves a critical role in tumor
invasion and progression, with microglia as a critical player. Our laboratory has previously demonstrated that
propentofylline, an atypical methylxanthine with central nervous system glial modulating and anti-inflammatory actions,
significantly decreases tumor growth in a GBM rodent model by preferentially targeting microglia. In the present study, we
used the CNS-1 rat glioma model to elucidate the mechanisms of propentofylline. Here we demonstrate that
propentofylline targets TROY, a novel signaling molecule up-regulated in infiltrating microglia, and not macrophages, in
response to CNS-1 cells. We identify Pyk2, Rac1 and pJNK as the downstream signaling molecules of TROY through western
blot analysis and siRNA transfection. We demonstrate that inhibition of TROY expression in microglia by siRNA transfection
significantly inhibits microglial migration towards CNS-1 cells similar to 10 mM propentofylline treatment. These results
identify TROY as a novel molecule expressed in microglia, involved in their migration and targeted by propentofylline.
Furthermore, these results describe a signaling molecule that is differentially expressed between microglia and
macrophages in the tumor microenvironment.
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Introduction
Glioblastoma mutiforme (World Heath Organization [WHO]
grade IV astrocytoma) is the most common and aggressive
primary brain cancer, and despite current therapies, median
survival is less than 2 years [1,2]. The tumor microenvironment
plays a critical role in glioma tumor growth. Microglia are a
resident monocyte population in the central nervous system (CNS),
which play a critical role in tumor initiation, invasion and growth
[3,4,5], and together with macrophages, make up as much as 30%
of the glioma tumor mass [3]. Glioma tumor cells actively recruit
microglia and peripheral macrophages to the tumor site [6,7].
Once there, these cells can secrete cytokines such as matrix
metalloproteinases (MMPs), which help increase glioma invasion
[8,9]. The underlying mechanisms involved in microglial response
to glioma are not completely understood, however, several
molecules have been identified.
One class of molecules involved in microglia and glioma cell
adhesion, migration and invasion are integrins [10]. Integrins are a
family of heterodimeric transmembrane proteins composed of two
subunits which mediate cell adhesion to the extra cellular matrix
(ECM) [11]. Tumor Necrosis Factor Receptors (TNFR) are another
large family of molecules often over expressed in glioma and involved
in microglial signaling [12,13,14]. One TNFR in particular,
TNFRSF19/TROY (Tumor Necrosis Factor Receptor of mouse
embryo), has been recently reported to be over expressed in glioma
and regulates migration of glioma cells through integrin signaling
pathways [15]. In humans, TROY is minimally expressed in the
brain with little to no expression in peripheral organs. Functions
attributed to TROY include forming a complex with NgR and
LINGO-1 in the peripheral nervous system to inhibit neurite
outgrowth in adult mice, mediation of osteoblast versus adipocyte
differentiation of human multipotent mesenchymal stromal cells and
promoting glioblastoma cell invasion [16,17,18]. However, little is
known about TROY’s possible role in immune cells.
Propentofylline (PPF) is an atypical synthetic methylxanthine [1-
(50-oxohexyl)-3-methyl-7-propylxanthine]. It has been studied
extensively in several CNS disease animal models of stroke, opioid
tolerance, and acute and chronic pain [19]. An important clinical
feature of PPF is its minimal adverse side-effect profile, demon-
strated in multiple clinical trials [19]. Known mechanisms include
inhibition of cyclic AMP (cAMP) and cyclic GMP phosphodies-
terases and action as a weak antagonist of the adenosine A1
receptor [20,21]. More generally, PPF is a glial modulator with
direct actions on microglia and astrocytes. We have previously
demonstrated that PPF treatment significantly decreases tumor
growth and increases survival in the CNS-1 rodent glioma model
[9]. PPF did not cause apoptosis or decrease proliferation of CNS-
1 tumor cells, but directly targeted microglia. Using in vitro
methods we demonstrated that PPF decreased microglial migra-
tion towards CNS-1 tumor cells and decreased MMP-9 expres-
sion. A decrease in microglia MMP-9 expression was also
determined in human glioma tissue samples. The effects of PPF
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37955were shown to be specific to microglia and not peripheral
macrophages.
With the failure of single marker targeted therapies, a GBM
therapy that targets glioma’s invasive potential as well as the tumor
promoting microenvironment are promising options. In this
report, we sought to further study and identify the mechanisms
of action of PPF. Here we demonstrate that PPF treatment
decreases TROY expression and ultimately decreases downstream
signaling molecules Pyk2, Rac1 and pJNK expression in microglia.
Herein, we present TROY as a novel molecule increased in
microglia in response to CNS-1 tumor cells, which further drives
microglial migration. Finally, we demonstrate differential expres-
sion of TROY in CNS resident microglia versus infiltrative
monocytes/macrophages. These results are profound, since
microglia and peripheral macrophages share several of the same
surface markers, and as such, these cells are rarely distinguished
when studying the role of immune cells in the GBM tumor
environment. In summary, TROY is a novel molecule involved in
microglial migration, which is targeted by PPF.
Materials and Methods
Animals and Cell Lines
This work was approved by the Dartmouth College Institutional
Animal Care and Use Committee (IACUC protocol 05-07-09). All
efforts were made to minimize the number of animals used and
their suffering. We used adult male Lewis Rats (250–300 g) for all
animal studies (Harlan Laboratories, Indianapolis, IN). For tumor
cell studies, we used the CNS-1 cell line - a rat glioma cell line,
(generously donated by Dr. William F. Hickey, Dartmouth
Medical School, Hanover, NH) [22]. IACUC protocols were not
established during the time CNS-1 cells line was developed for
citation purposes (1990), however, the highest ethical standards in
animal care were upheld during use of these animals. The cell line
has been tested within the last year by verification of GFAP
expression with immunohistochemistry. Propentofylline was pur-
chased from Toronto Research Chemicals (North York, ON).
Cell Culture
Highly purified microglial cultures were prepared as previously
described [23]. Briefly, cortices were harvested from postnatal day
2–3 (P2–P3) Lewis rat pups, minced and incubated with trypsin/
EDTA (Mediatech Manassas, VA). The supernatant was then
replaced with DMEM (Mediatech, Manasses VA) supplemented
with 10% fetal bovine serum (Hyclone Logan, UT), 1.1%
GlutaMax (Invitrogen Carlsbad, CA), and 1% penicillin/strepto-
mycin (100 U/ml penicillin, 100 mg/ml streptomycin, Mediatech,
Manassas, VA) containing 2000 units DNase (Sigma St Louis,
MO). The tissue was mechanically disrupted by trituration, the cell
suspensions were centrifuged, and the cells resuspended in media
without DNase. A small aliquot of cells were stained for trypan
blue exclusion for counting, then cells were plated at 1610
6 cells
per 75 cm
2 flask. Cultures were maintained at 37uC with 5% CO2,
and media was changed every 3–4 days. After 10 days in vitro (DIV
10) microglia were harvested by gently shaking the flasks by hand
for 1 minute. The resulting cells were found to be .98% microglia
by staining with CR3/CD11b antibody (generous gift from Dr
William F. Hickey). Cells were used immediately for migration and
western experiments. Peripheral macrophages were obtained from
peritoneal lavage of adult rats. Briefly, 10 ml of cold PBS
(Mediatech Manassas, VA) was injected into the rat peritoneum,
the stomach was massaged, and fluid was subsequently removed.
Cells were centrifuged and pellets were resuspended in complete
media. Resuspended cells were plated in a 75 mm
2 flask and
washed the next day, leaving adherent macrophages on the flask.
The resulting cells were found to be .98% macrophages by
staining with CD11b antibody (mouse mAb clone WT.5; BD
Franklin Lakes, NJ). CNS-1 cultured media was obtained by
culturing 3610
5 CNS-1 cells in 500 mL of DMEM for 3 days, and
then collecting the supernatant.
Migration
The optimal experimental procedures for microglial migration in
Costar Transwell plates have been previously reported [23,24]. Cell
migration was studied using Costar Transwell plates (6.5 mm
diameter insert, 8.0 mm pore size, polycarbonate membrane,
Corning Sparks, MD). Briefly, CNS-1 cells were plated at a density
of 3610
5 cells per 500 ml in the bottom wells 3 days prior to the
migration experiment. Microglia were harvested as described above,
counted, and resuspended in serum-free media at 1610
5 cells per
100 ml, placed in siliconized low-adhesion microcentrifuge tubes, and
treated with PPF (0.01 mM–100 mM) for 2-hour. Microglia under-
going siRNA transfection was first plated, transfected and migration
was performed the following day. Cells were counted post-treatment
with trypan blue to ensure survival (.99% viability) and then added
(1610
5 cells per 100 ml) to the top chamber of a transwell plate with
fibronectin-coated membranes and 500 mlo fC N S - 1c e l l si nt h e
bottom well. After 2 hour incubation, any cells remaining on top of
the membrane were washed. The membranes were rinsed with PBS,
the migrated cells were fixed with 2% formaldehyde in PBS,
permeabilized with 0.01% Triton X-100 (Sigma St Louis, MO) in
PBS, stained with crystal violet (Sigma St Louis, MO), and rinsed
twice with dH2O. The membranes were then dried, inverted, and
mounted on microscope slides for analysis. Images of 10 random
fields (206magnification) for each membrane were captured at room
temperature via a Q-fired cooled CCD camera attached to an
Olympus microscope and counted by hand with aid of SigmaScan
Pro imaging analysis software (SigmaScan Chicago, IL). Counts from
all 10 fields were averaged to give a mean cell count for each
membrane. All experiments were performed at least three times with
n=3 per trial. Results are expressed as mean cell migration relative to
vehicle control 6 S.D.
Flow Cytometry
For flow cytometry analysis on rat tumors, rats were first
perfused with cold PBS and the tumors and cortices were
removed. Tissue was minced with scalpels, spun down at
1250 rpm for 10 minutes and then resuspended in digestion
media (10 mL HBSS, 2,000 U DNase, 400 mL Collagenase D).
Tissue was incubated in a 37uC water bath for 40 minutes and
then spun down (1250 rpm for 10 minutes). Tissue was resus-
pended in Percoll media (10.5 mL HBSS and 4.5 mL Percoll) and
spun down for 30 minutes at 2000 rpm on slow acceleration and
deceleration. Fc receptors were blocked using FBS for 15 minutes
before staining. Cells were first stained with anti-TROY for 1 hr
on ice in PBS. Cells were washed with cold PBS and then stained
with anti-CD45 PE 1:200 (BD Pharmingen San Jose, CA), anti-
CDllb-FITC 1:100 (BD Pharmingen San Jose, CA) and anti-rabbit
APC 1:100 (Santa Cruz Santa Cruz, CA) on ice in the dark for
1 hr. Cells were washed and then analyzed. For microglia cells,
cells were collected then incubated at 37uC in 24-well plates
(Falcon Franklin Lakes, NJ) at a concentration of 3610
5 cells/well
with CNS-1 supernatant for 1 hr with PPF (0.01 mM- 10 mM).
Cells were then trypsinized, washed and stained on ice in PBS for
30 minutes with anti-CDllb FITC. Fc receptors were blocked
using FBS for 15 minutes before staining. All flow cytometry
experiments were performed on a FACSCanto (BD Bioscience
Franklin Lakes, NJ).
TROY in Microglia Is Targeted by Propentofylline
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37955Figure 1. TROY is expressed in microglia in response to CNS-1 tumor stimulation. (A) TROY western blot of microglia cultured with CNS-1
conditioned media over time. (B) A graphical representation of differential TROY expression in microglia cultured with CNS-1 conditioned media over
time (*=p,0.05). Graph is representative of three western blots from three replicates.
doi:10.1371/journal.pone.0037955.g001
Figure 2. Microglia increase Pyk2, Rac1 and pJNK expression in response to CNS-1 conditioned media. (A) Pyk2 and Rac1 western blot
of microglia cultured with CNS-1 conditioned media over time. (B) pJNK and tJNK western blot of microglia cultured with CNS-1 conditioned media
over time. (C) A graphical representation of differential pyk2 expression in microglia cultured with CNS-1 conditioned media over time (*=p,0.05).
(D) A graphical representation of differential Rac1 expression in microglia cultured with CNS-1 conditioned media over time (*=p,0.05). (E) A
graphical representation of differential pJNK expression in microglia cultured with CNS-1 conditioned media over time (*=p,0.05). Graphs are
representative of three western blots from three replicates.
doi:10.1371/journal.pone.0037955.g002
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CNS-1 cells, microglia, or macrophages were plated at a cell
density of 3610
5 cells/well in a 12-well plate (Falcon Franklin
Lakes, NJ) and treated with PPF (0.01 mM–10 mM) or PBS when
needed. The cells were then collected with Lamelli buffer and beta
mercapto-ethanol and the protein was then quantified using the
Lowry method (DC Assay, Bio-Rad Hercules, CA). Protein (40 mg)
and a standard marker were subjected to SDS-PAGE (10% gels,
Bio-Rad), transferred to PVDF membranes (Bio-Rad Hercules,
CA),and blocked with 5%milk in TBS-Tween 20 (0.05%, Sigma St
Louis, MO). The membranes were probed with rabbit anti-TROY
(1:20, AbCam Cambridgeshire, UK), rabbit anti-Pyk2 (1:500,
AbCam Cambridgeshire, UK), rabbit anti-pJNK (1:500, BD
Pharmingen San Jose, CA), rabbit anti-JNK (1:1000, BD Pharmin-
gen San Jose, CA) or mouse anti-Rac1 (1:250, AbCam Cambridge-
shire, UK) primary antibody for 16 hours at 4uC. Membranes were
washed three times, and then incubated with goat anti-rabbit HRP-
conjugated secondary (1:300) antibody or anti-mouse HRP-
conjugated secondary (1:300) for 1 hour at 22uC. Visualization
was done with SuperSignal West Femto Maximum Sensitivity
Substrate (Pierce Rockford, IL) for 5 minutes and imaged using the
Syngene G-Box (Synoptics Frederick, MD). Cellular suspensions
were analyzed by stripping membranes and reprobing them with
mouse monoclonal anti-b-actin primary antibody (1:1000, Abcam
Cambridgeshire, UK). Band intensities were quantified using the
analysis software provided with the Syngene G-Box. The relative
intensity of bands were divided by the intensity of the b-actin band
and then compared to control. Data are expressed as fold change in
band intensity normalized to naı ¨ve control 6 S.D.
Small interference RNA knockdown
Small interference RNA (siRNA) oligonucleotides specific for
TROY (#1:s144862, #2:s144863, #3:s144864) were validated by
and purchased from Invitrogen (Grand Island, NY). Transient
transfection was carried out using iFect (Neuromics Edina, MN) as
previously described [25]. Briefly, microglia were plated at 3610
5
cells/well in a 12-well plate. Once cells had adhered, they were
transfected with 1 mg siRNA. Control samples were treated with
empty vector siRNA (Sigma St Louis, MO) or iFect reagent alone.
Cells were left in microglia media (10% fetal bovine serum
(Hyclone Logan, UT), 1.1% GlutaMax (Invitrogen Carlsbad, CA),
and 1% penicillin/streptomycin (100 U/ml penicillin, 100 mg/ml
streptomycin, Mediatech, Manassas, VA)) at 37uC with 5% CO2
overnight and then used the following day for experiments.
Results
TROY is expressed in microglia in response to CNS-1
tumor stimulation
We sought to investigate if TROY may be involved in microglial
recruitment to the tumor site. We first determined whether microglia
express TROY. Microglia display low levels of TROY expression
when cultured inDMEM, however,TROY expression is significantly
(p,0.05) increased in response to CNS-1 conditioned media (Fig. 1).
After 1 hour, TROY expression was increased by over 100%.
Figure 3. Propentofylline decreases TROY expression in microglia. (A) TROY western blot of microglia cultured with CNS-1 conditioned
media and treated with PPF. (B) A graphical representation of differential TROY expression microglia cultured with CNS-1 conditioned media and
treated with PPF (*=p,0.05). Graph is representative of three western blots from three replicates.
doi:10.1371/journal.pone.0037955.g003
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peritoneal macrophages in response to CNS-1 conditioned media
(data not shown) nor in CNS-1 tumor cells (Fig. 1).
Microglia increase TROY signaling molecules in response
to CNS-1 conditioned media
To further investigate TROY signaling we asked whether Pyk2,
Rac1 and pJNK are increased in microglia in response to CNS-1
conditioned media after the observed increase in TROY
expression. Pyk2 and Rac1 have recently been reported to be
involved in TROY expression in human glioma cell lines and both
proteins are involved in cellular migration and invasion. The
protein kinase, pJNK, is further downstream and has also been
linked to TROY expression.
Microglia were cultured with CNS-1 conditioned media over
time and changes in protein expression were analyzed by western
blot analyses. Both Pyk2 and Rac1 significantly increased
expression over time (p,0.05) (Fig. 2A,C,D). Pyk2 was
significantly increased by 90 minutes compared to time 0, while
Rac1 was significantly increased at 120 minutes (Fig. 2D). The
tyrosine kinase, pJNK was significantly increased at 30 minutes
compared to time 0, with a further increase at 60 minutes
(P,0.05) (Fig. 2B,E). There was no significant change in tJNK
(Fig. 2E).
PPF decreases both TROY expression and downstream
signaling of Pyk2, Rac1 and pJNK in microglia
As mentioned previously, PPF has a direct mechanism on
microglial migration. It has also been previously reported that PPF
decreases integrin CD11b expression (Figure S1) [19]. Recogniz-
ing TROY’s shared downstream signaling with integrins (Pyk2,
Rac1) and PPF’s inhibition of microglial migration, we asked if
TROY is a target for PPF. Microglia were co-cultured in vitro with
CNS-1 conditioned media for 1 hour and treated with PPF
(0.01 mM–10 mM). PPF significantly decreased TROY expression
in microglia in a dose dependent manner (p,0.05) (Fig. 3), with
decreased expression by almost 50% at 10 mM (Fig. 3).
Next, Pyk2, Rac1 and pJNK expression with PPF treatment was
assessed. Microglia were cultured with CNS-1 conditioned media
and treated with PPF for 90 minutes. Microglia treated with
TROY siRNA was used as a positive control for inhibition of the
TROY signaling pathway in microglia. TROY siRNA treatment
significantly (p,0.05) decreased Pyk2, Rac1 and pJNK signaling,
as expected. PPF significantly inhibited Pyk2 with a dose as low as
0.1 mM compared to media (p,0.05) (Fig. 4A,C). Rac1 was
significantly inhibited with PPF treatment; however, this was at a
dose of 10 mM (Fig. 4A,D). PPF further inhibited pJNK expression
in microglia compared to media at both 1 mM and 10 mM
(Fig. 4E). There was no decrease in tJNK with PPF or siRNA
blockade.
Figure 4. Propentofylline decreases Pyk2, Rac1 and pJNK. (A) Pyk2, Rac1 and pJNK western blot of microglia cultured with CNS-1 conditioned
media and treated with PPF. (B) pJNK and tJNK western blot of microglia cultured with CNS-1 conditioned media and treated with PPF. (C) A graphical
representation of differential pyk2 expression in microglia cultured with CNS-1 conditioned media and treated with PPF (*=p,0.05). (D) A graphical
representation of differential Rac1 expression in microglia cultured with CNS-1 conditioned media and treated with PPF (*=p,0.05). (E) A graphical
representation of differential pJNK expression in microglia cultured with CNS-1 conditioned media and treated with PPF (*=p,0.05). Graphs are
representative of three western blots from three replicates.
doi:10.1371/journal.pone.0037955.g004
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migration towards CNS-1 tumor cells
To determine the functional role of TROY in microglia, we
used siRNA to knock down TROY expression in primary
microglia (Fig. 5A). Three different siRNAs were tested. The
siRNA #2 demonstrated the strongest knockdown and was used
for Boyden chamber migration experiments. Negative siRNA and
iFect reagent were used as controls while 10 mM PPF was used as a
positive control for inhibition of microglial migration. Migration of
microglia towards CNS-1 cells was significantly inhibited (80%
decrease in migration) compared to media and negative siRNA
(p,0.05). Inhibition of migration with TROY knock down was
comparable to 10 mM PPF. There was no statistical difference
between TROY knockdown and PPF.
TROY is expressed in tumor infiltrating microglia in vivo
and decreased by propentofylline
To confirm TROY expression in vivo, Lewis rats were inoculated
with 3610
5 CNS-1 cells. Lewis rats without tumors were used as a
control. At day 10, rats were euthanized and tumors or cerebellum





+) and TROY (Fig. 6A). TROY was
highly expressed in tumor infiltrating microglia compared to
monocytes (Fig. 6A). Furthermore, microglia isolated from non-
tumor rats displayed minimal TROY expression (Fig. 6A).
To study PPF’s effects on TROY in vivo, rats were inoculated
with CNS-1 cells and tumors were grown for 8 days. Rats were
then treated with 50 mg/kg of PPF or saline i.p. daily for two days.






TROY. PPF decreased expression of TROY in tumor infiltrating
microglia compared to saline treated rats (Fig. 6B).
Discussion
We demonstrate in these studies that 1) TROY is expressed in
microglia in response to CNS-1 cells, 2) Pyk2, Rac1 and pJNK are
downstream signaling molecules of TROY in microglia 3) PPF
decreases TROY expression and its downstream molecules and 4)
TROY is involved in microglia migration towards CNS-1 cells.
Glioma has a high infiltrative population of microglia and
peripheral macrophages to the tumor site [3]. The infiltrative
property of gliomas is cited as a key reason for low survival and
tumor recurrence [26]. It has been established that these infiltrative
immune cells have a direct role in increasing glioma cell invasion
and growth [8,27]. The recent past has been witness to promising
targeted therapies forglioma, unfortunately thesesingle targets have
demonstrated unpromising results in clinical trials in GBM patients
[28]. The failure to also target the strong tumor promoting
microenvironment is a possible reason for the lack of success. Our
previous work identified PPF as a novel drug for GBM that targets
Figure 5. TROY knockdown results in a decrease of microglial migration towards CNS-1 tumor cells. (A) Western blot demonstrating
decreased TROY expression in microglia cultured with CNS-1 conditioned media and treated with TROY siRNA. (B) Microglia were treated with TROY
siRNA, and then migrated towards CNS-1 cells. Migration of microglia in response to CNS-1 cells is significantly decreased compared to media
(*=p,0.05).
doi:10.1371/journal.pone.0037955.g005
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further identify the mechanism of PPF’s actions.
In this study we demonstrate that PPF decreases the TNFRSF
member TROY, which is involved in microglial migration
towards CNS-1 cells. TROY is a unique TNFRSF member
whose expression is strictly controlled [29]. TROY is highly
expressed in embryonic development, and then minimally
expressed in the adult, indicating that continual expression is
unfavorable [30,31]. However, TROY is expressed once again in
microglia in response to CNS-1 cells, suggesting this receptor plays
Figure 6. TROY is expressed in tumor infiltrating microglia, not macrophages. (A) Lewis rats were implanted with 3610
5 CNS-1 cells.





+) and TROY. Gating is shown in figure, histogram is representative of 6 rats/group. (B) Lewis rats were implanted with CNS-1 cells and then





+) and TROY. Histogram is representative of 3 rats/group.
doi:10.1371/journal.pone.0037955.g006
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ultimately effecting glioma growth and invasion. Our studies in
microglia were conducted in a CNS-1 rodent glioma model. This
rodent model does not express TROY in the CNS-1 tumor cells,
which enabled specific studies of TROY expression in the tumor
microenvironment. However, animal models do not fully recapit-
ulate the genetic diversity of the human disease and TROY
expression in microglia and infiltrating macrophages needs to be
confirmed in human glioma tissue. Although TROY is not
expressed in CNS-1 cells, expression has been cited in human
glioma cell lines [15]. If TROY expression is confirmed in human
microglia, this may represent a novel biomarker, which is
expressed in both glioma tumor cells and the tumor microenvi-
ronment.
We identify Pyk2, Rac1 and pJNK as downstream signaling
molecules for TROY. Pyk2 and Rac1 are increased after
90 minutes and 120 minutes in microglia cultured in CNS-1
conditioned media. This is after the 60 minute time point when
TROY expression is increased. The tyrosine kinase pJNK has an
initial increase at 30 minutes before TROY is increased. However,
there is a second increase in expression at 60 minutes, which
correlates with TROY expression. Other signaling molecules
known to increase pJNK, such as PDGF, can explain the initial
increase in pJNK expression at time 30 minutes [26]. The TROY
pathway was further confirmed by siRNA knockdown of TROY
in microglia, which demonstrated a decrease in Pyk2, Rac1 and
pJNK. All three of these molecules have been linked to migration
and invasion, further supporting TROY’s role in microglial
migration. It is still unknown what in the CNS-1 conditioned
media initiates TROY expression or what the ligand is that signals
through TROY in microglia. Future experiments will focus on
identifying signaling molecules from CNS-1 cells that promote
TROY expression and signaling in microglia.
Most research studying microglia and infiltrative macrophages
in the glioma microenvironment do not differentiate these two
populations. To date there is not a single marker that can easily
distinguish the two monocyte populations. Currently, staining
based on CD45 expression (high vs low) is the best method,
however, the gating of these two populations can often be
subjective. In this paper we demonstrate TROY as a novel marker
that differentiates microglia and macrophages in the tumor
microenvironment. It remains to be investigated if this molecule
differentiates microglia and macrophages in human tissue or in
other disease states. However, it does provide evidence of
differential function and supports further investigation into how
each of these two populations may differentially affect glioma
tumor growth.
In summary, we present TROY as a novel receptor expressed in
microglia in response to CNS-1 cells, involved in microglia
migration, and targeted by propentofylline.
Supporting Information
Figure S1 Histogram representation of CDllb expres-
sion in microglia with PPF treatment. Microglia were
cultured in vitro with CNS-1 conditioned media for 60 minutes
then treated with propentofylline for another 60 minutes. CDllb
expression was analyzed by FACS. Propentofylline decreased
expression of CDllb with increasing dosages. Histogram is
representative image of n=3.
(TIF)
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